organized and hosted by research institute for nuclear medicine, tehran university of medical sciences, tehran, iran

A practical guidance document on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors is being published this month in the European Journal of Nuclear Medicine and Molecular Imaging (1). This document is the result of close collaboration among experts in the field of PRRNT from the International Atomic Energy Agency; the Radionuclide Therapy, Oncology, Dosimetry, and Radiophar...

The cost of radiopharmaceutical materials is highly expensive compared with other resources employed in nuclear medicine department. Hence, inefficient utilization of these costly materials will lead to waste and more financial burden on the healthcare system, increasing the patient waiting list for important diagnostic procedures, especially in those with need urgent care on time. The availabl...

Quality control (QC) procedures should always be performed following radiopharmaceutical preparation and prior to patient administration. The main aim of QC is to ensure optimal radiopharmaceutical product properties except for some short half-life tracers such as some positron emission tomography (PET) imaging probs. by dispensing a radiopharmaceutical of the highest quality the risk of having...

For years many have employed the concept of "total-body dose" or "whole-body dose," i.e., the total energy deposited in the body divided by the mass of the body, when evaluating the risks of different nuclear medicine procedures. The effective dose equivalent (H ), first described in ICRP E Publication 26, has been accepted by some as a better quantity to use in evaluating the total risk of a p...